This clinical research study is following changes in bone mineral density over time when Myfembree is used for up to 4 years and for 1 year after treatment is stopped. Currently, this medication is approved by the FDA for up to 2 years of use for the management of premenopausal women with heavy menstrual bleeding associated with uterine fibroids or moderate to severe pain associated with endometriosis.
This study is an open-label study (that means all participants know exactly what medication they are taking) and NO participants will receive placebo pills or sugar pills.
You may qualify for the Myfembree study if you:
- Are a premenopausal woman between the ages of 18 and 50
- Have a diagnosis of uterine fibroids associated with heavy menstrual bleeding
- Have moderate-to-severe pain associated with endometriosis
- Are not pregnant, actively trying to get pregnant or breastfeeding
- Do not have osteoporosis (thinning, weak bones) or any other bone disease
Eligible participants will receive all study-related care and investigational medication at no cost. In addition, eligible participants may receive compensation for time and travel. No health insurance is required.
For more information about this study, please call (316) 425-6333.
